RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma

References

• Lessnick SL, Ladanyi M. Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu Rev Pathol 2012; 7:145 - 59; http://dx.doi.org/10.1146/annurev-pathol-011110-130237; PMID: 21942527
   PubMed Web of Science ®Google Scholar
• Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000; 25:315 - 9; http://dx.doi.org/10.1038/77083; PMID: 10888881
   PubMed Web of Science ®Google Scholar
• Dallol A, Hesson LB, Matallanas D, Cooper WN, O’Neill E, Maher ER, et al. RAN GTPase is a RASSF1A effector involved in controlling microtubule organization. Curr Biol 2009; 19:1227 - 32; http://dx.doi.org/10.1016/j.cub.2009.05.064; PMID: 19559616
   PubMed Web of Science ®Google Scholar
• Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 2009; 1796:114 - 28; PMID: 19344752
   PubMed Web of Science ®Google Scholar
• Underhill-Day N, Hill V, Latif F. N-terminal RASSF family: RASSF7-RASSF10. Epigenetics 2011; 6:284 - 92; http://dx.doi.org/10.4161/epi.6.3.14108; PMID: 21116130
   PubMed Web of Science ®Google Scholar
• Avigad S, Shukla S, Naumov I, Cohen IJ, Ash S, Meller I, et al. Aberrant methylation and reduced expression of RASSF1A in Ewing sarcoma. Pediatr Blood Cancer 2009; 53:1023 - 8; http://dx.doi.org/10.1002/pbc.22115; PMID: 19637319
   PubMed Web of Science ®Google Scholar
• Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19:491 - 505; http://dx.doi.org/10.1016/j.devcel.2010.09.011; PMID: 20951342
   PubMed Web of Science ®Google Scholar
• Cooper WN, Dickinson RE, Dallol A, Grigorieva EV, Pavlova TV, Hesson LB, et al. Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. Oncogene 2008; 27:1805 - 11; http://dx.doi.org/10.1038/sj.onc.1210805; PMID: 17891178
   PubMed Web of Science ®Google Scholar
• Kaira K, Sunaga N, Tomizawa Y, Yanagitani N, Ishizuka T, Saito R, et al. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers. Int J Oncol 2007; 31:169 - 73; PMID: 17549418
   PubMed Web of Science ®Google Scholar
• Luo D, Ye T, Li TQ, Tang P, Min SD, Zhao GF, et al. Ectopic expression of RASSF2 and its prognostic role for gastric adenocarcinoma patients. Exp Ther Med 2012; 3:391 - 6; PMID: 22969901
   PubMed Web of Science ®Google Scholar
• Schagdarsurengin U, Richter AM, Hornung J, Lange C, Steinmann K, Dammann RH. Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Mol Cancer 2010; 9:264; http://dx.doi.org/10.1186/1476-4598-9-264; PMID: 20920251
   PubMed Web of Science ®Google Scholar
• Imai T, Toyota M, Suzuki H, Akino K, Ogi K, Sogabe Y, et al. Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma. Cancer Sci 2008; 99:958 - 66; http://dx.doi.org/10.1111/j.1349-7006.2008.00769.x; PMID: 18294275
   PubMed Web of Science ®Google Scholar
• Nagasaka T, Tanaka N, Cullings HM, Sun DS, Sasamoto H, Uchida T, et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst 2009; 101:1244 - 58; http://dx.doi.org/10.1093/jnci/djp265; PMID: 19700653
   PubMed Web of Science ®Google Scholar
• Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 2003; 278:28045 - 51; http://dx.doi.org/10.1074/jbc.M300554200; PMID: 12732644
   PubMed Web of Science ®Google Scholar
• Clark J, Freeman J, Donninger H. Loss of RASSF2 Enhances Tumorigencity of Lung Cancer Cells and Confers Resistance to Chemotherapy. Mol Biol Int 2012; 2012:705948; http://dx.doi.org/10.1155/2012/705948; PMID: 22693671
   PubMedGoogle Scholar
• Cooper WN, Hesson LB, Matallanas D, Dallol A, von Kriegsheim A, Ward R, et al. RASSF2 associates with and stabilizes the proapoptotic kinase MST2. Oncogene 2009; 28:2988 - 98; http://dx.doi.org/10.1038/onc.2009.152; PMID: 19525978
   PubMed Web of Science ®Google Scholar
• Donninger H, Hesson L, Vos M, Beebe K, Gordon L, Sidransky D, et al. The Ras effector RASSF2 controls the PAR-4 tumor suppressor. Mol Cell Biol 2010; 30:2608 - 20; http://dx.doi.org/10.1128/MCB.00208-09; PMID: 20368356
   PubMed Web of Science ®Google Scholar
• Song H, Kim H, Lee K, Lee DH, Kim TS, Song JY, et al. Ablation of Rassf2 induces bone defects and subsequent haematopoietic anomalies in mice. EMBO J 2012; 31:1147 - 59; http://dx.doi.org/10.1038/emboj.2011.480; PMID: 22227519
   PubMed Web of Science ®Google Scholar
• Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, et al. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer 2009; 8:42; http://dx.doi.org/10.1186/1476-4598-8-42; PMID: 19570220
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143 - 7; http://dx.doi.org/10.1126/science.284.5411.143; PMID: 10102814
   PubMed Web of Science ®Google Scholar
• Gharanei S, Zatyka M, Astuti D, Fenton J, Sik A, Nagy Z, et al. Vacuolar-type H+-ATPase V1A subunit is a molecular partner of Wolfram syndrome 1 (WFS1) protein, which regulates its expression and stability. Hum Mol Genet 2013; 22:203 - 17; http://dx.doi.org/10.1093/hmg/dds400; PMID: 23035048
   PubMed Web of Science ®Google Scholar
• Dallol A, Al-Maghrabi J, Buhmeida A, Gari MA, Chaudhary AG, Schulten HJ, et al. Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2012; 21:2069 - 75; http://dx.doi.org/10.1158/1055-9965.EPI-12-0755; PMID: 23010642
   PubMed Web of Science ®Google Scholar